Showing results (131-140 of 146) with videos related to
Sort By:
Pageof 15
The New England Journal of Medicine|June 2, 2025
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based ChemotherapyGiannis Mountzios, Longhua Sun, Byoung Chul Cho, et al.Lung Cancer (Amsterdam, Netherlands)|July 30, 2022
PD-L1 assessment in cytology samples predicts treatment response to checkpoint inhibitors in NSCLCSally C M Lau, Madhumitha Rabindranath, Jessica Weiss, et al.Lancet (London, England)|May 22, 2007
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trialsElmar A Joura, Sepp Leodolter, Mauricio Hernandez-Avila, et al.Nature Immunology|July 14, 2022
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapyGiselle M Boukhaled, Ramy Gadalla, Heidi J Elsaesser, et al.International Journal of Cancer|October 16, 2010
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccineKevin A Ault, Elmar A Joura, Susanne K Kjaer, et al.Advances in Marine Biology|January 22, 2016
Humpback Dolphins in Hong Kong and the Pearl River Delta: Status, Threats and Conservation ChallengesLeszek Karczmarski, Shiang-Lin Huang, Carmen K M Or, et al.Biorxiv : the Preprint Server for Biology|May 3, 2023
In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1 -mutant lung cancerJiehui Deng, David H Peng, David Fenyo, et al.Cancer Cell|December 16, 2022
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibitionYuanwang Pan, Han Han, Hai Hu, et al.Cancer Prevention Research (Philadelphia, Pa.)|October 1, 2009
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesionsSusanne K Kjaer, Kristján Sigurdsson, Ole-Erik Iversen, et al.BMJ (Clinical Research Ed.)|July 22, 2010
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial, Joakim Dillner, Susanne K Kjaer, et al.Pageof 15